• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

What are the Indications for RASopathy Prenatal Testing?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • RASopathies are a group of relatively common genetic conditions
    • 1:1000 to 1:2500 live births
    • Likely more common in the prenatal period
    • Example of important rasopathy is Noonan syndrome which can appear prenatally with cystic hygroma or enlarged nuchal translucency (NT) but normal chromosomes
  • Scott et al. (Genetics in Medicine, 2021) studied genotype–phenotype correlations to further understand the role of prenatal testing for these disorders

METHODS:

  • Retrospective study | Systematic Review (2021 to 2019)
  • Population
    • Fetuses referred for genetic testing because of findings suggestive of RASopathy
    • Chromosomal microarray–negative cases
  • Study design
    • Most cases sent for testing examined 11 RASopathy genes
    • The authors used postnatal cohorts (25 patients with available prenatal information and 108 institutional database genotypes) and the NSeuroNet database

RESULTS:

  • 352 chromosomal microarray–negative cases
  • Prevalence of ultrasound findings
    • Increased nuchal translucency (NT): 74%
    • Cystic hygroma: 58%
  • NT
    • Diagnostic yield greatest for NT >6mm (20%)
    • Yield very low for isolated NT <6mm (1%; 1/90)
  • Nuchal fold
    • Diagnostic yield was 25% for increased nuchal fold
  • Pathogenic variants identified
    • Overall: 14% (50 cases)
  • The following ultrasound findings had diagnostic yields >20%
    • Effusions
    • Hydrops
    • Congenital heart disease
  • Diagnostic yield was greater for the following
    • Hypertrophic cardiomyopathy
    • Persistent or associated cystic hygroma
    • Any suggestive finding plus renal anomaly or polyhydramnios
    • ≥2 ultrasound findings
  • Largest prenatal contributors of pathogenic variants
    • PTPN11: 30%
    • RIT1: 16%
    • RAF1: 14%
    • HRAS: 12%
  • HRAS, LZTR1, and RAF1 variants correlated with hydrops/effusions
    • RIT1 correlated with prenatal onset of hypertrophic cardiomyopathy

CONCLUSION:

  • In the setting of prenatal evidence of lymphatic abnormality or congenital heart defects where the microarray result is normal, fetal genetic testing appears to be warranted for Noonan syndrome and other RASopathies
  • They authors conclude

…after a normal CMA, RASopathy prenatal testing should be offered when any prenatal US finding suggestive of lymphatic dysplasia (CH, increased NT or NF, hydrops, effusions, other lymphatic anomalies) or suggestive CHD (like valvular dysplasia and/or HCM) is found alone or in association, except for isolated increased NT below 6 mm or isolated increased NF

Learn More – Primary Sources:

When to test fetuses for RASopathies? Proposition from a systematic analysis of 352 multicenter cases and a postnatal cohort

Now You Can Get Mobile-Friendly ObG Clinical Research Summaries with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Large NT but Normal Karyotype? Noonan Syndrome Basics
Practical obstetrics info for your women's healthcare practice
Cystic Hygroma: Definition, Genetics and Prognosis
How Common is Noonan Syndrome When the NT is Large but Chromosomes Appear Normal?
Is There Value to an Early Anatomy Scan with an Enlarged NT?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site